ESMO 2021 Prostate Cancer - Results from #20

Viewing 21-40 of 74 articles

ESMO 2021: A Discussion on the Role of Abiraterone in Combination with Docetaxel and the Role of Abiraterone in Combination with ADT

ESMO 2021: A Phase 3 Trial with a 2x2 Factorial Design in Men with De Novo Metastatic Castration-Sensitive Prostate Cancer: Overall Survival with Abiraterone Acetate plus Prednisone in PEACE-1

ESMO 2021: Health-Related Quality of Life, Pain and Safety Outcomes in the Phase 3 VISION Study of 177Lu-PSMA-617 in Patients with mCRPC

ESMO 2021: Abiraterone Acetate plus Prednisolone with or Without Enzalutamide Added to Androgen Deprivation Therapy Compared to ADT Alone for Men with High-Risk Non-Metastatic Prostate Cancer

ESMO 2021: Darolutamide Maintenance in mCRPC Previously Treated with Novel Hormonal Agents and Non-Progressive Disease After Subsequent Treatment with a Taxane: A Randomized Double-Blind Placebo-Controlled Phase II Trial (SAKK 08/16)

ESMO 2021: A Phase 3 Trial With a 2x2 Factorial Design in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer: Overall Survival With Abiraterone Acetate Plus Prednisone in PEACE-1

ESMO 2021: Abiraterone Acetate Plus Prednisolone With or Without Enzalutamide Added to ADT Compared to ADT Alone for Men With High-Risk Non-Metastatic Prostate Cancer: Combined Analysis From Two Comparisons in the STAMPEDE Platform

ESMO 2021: Discussion on the Final Overall Survival Analysis From the ARCHES Study: Enzalutamide + ADT in Men With mHSPC

ESMO 2021: Discussion on the PRINCE Trial of 177Lu-PSMA-617 in Combination With Pembrolizumab for Metastatic Castration-Resistant Prostate Cancer

ESMO 2021: Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer: Results of Expanded Cohort 6 of the COSMIC-021 Study

ESMO 2021: PRINCE: Interim Analysis of the Phase Ib Study of 177Lu-PSMA-617 in Combination With Pembrolizumab for Metastatic Castration Resistant Prostate Cancer

ESMO 2021: Cabozantinib in Combination with Atezolizumab in Patients with mCRPC: Results of Expanded Cohort 6 of the COSMIC-021 Study: Invited Discussant

ESMO 2021: Final Overall Survival Analysis From ARCHES: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Enzalutamide + ADT in Men With mHSPC

ESMO 2021: Real-World Utilization of Advanced Therapies by Metastatic Site and Age Among Patients With mCSPC: A Medicare Database Analysis

ESMO 2021: Estimation of Overall Survival With Subsequent Treatment Effect by Applying Inverse Probability of Censoring Weighting in the LATITUDE Study

ESMO 2021: Pembrolizumab Plus Olaparib in Patients with Docetaxel-Pretreated mCRPC: Update of KEYNOTE-365 Cohort A with a Minimum of 11 Months of Follow-Up for all Patients

ESMO 2021: Circulating Tumor Cell Morphologic Sub-Types Present Prior to Treatment in the CARD Trial Identify Therapy Resistance

ESMO 2021: Real-World Treatment Patterns in Metastatic Hormone-Sensitive Prostate Cancer Patients in the US

ESMO 2021: SAABR: Single Arm Phase II Study of Abiraterone + Atezolizumab + GnRH Analog and SBRT to the Prostate in Men with Newly Diagnosed mHSPC

ESMO 2021: Apalutamide for Advanced Prostate Cancer in Older Patients: Combined Analysis of TITAN & SPARTAN

1
2
3
4